Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press135510.17650/1726-9776-2021-17-2-139-144REVIEWSОБЗОРЫApplication of the in silico approach in the study of critical genes predicting chemotherapeutic response to oxaliplatin in treatment of prostate cancer (literature reviev)Применение подхода in silico в исследовании критических генов, прогнозирующих химиотерапевтический ответ на оксалиплатин при лечении рака предстательной железы (обзор литературы)https://orcid.org/0000-0002-1550-6069LoginovaM. V.ЛогиноваМ. В.
Russian Federation

Mariya V. Loginova.

73 / 1 Prospekt Oktyabrya, Ufa 450054, Republic of Bashkortostan.

Логинова Мария Владиславовна - врач-онколог онкологического отделения противоопухолевой лекарственной терапии ГАУЗ РКОД МЗ РБ; аспирант кафедры урологии с курсом ИДПО БГМУ.

450054 Уфа, проспект Октября, 73 / 1.

mariialoginova25@gmail.comhttps://orcid.org/0000-0003-2125-4897PavlovV. N.ПавловВ. Н.
Russian Federation

3 Lenina St., Ufa 450008, Republic of Bashkortostan.

Республика Башкортостан, 450008 Уфа, ул. Ленина 3.

https://orcid.org/0000-0001-9499-5632GilyazovaI. R.ГилязоваИ. Р.
Russian Federation

3 Lenina St., Ufa 450008, Republic of Bashkortostan; 71 Prospekt Oktyabrya, Ufa 450098, Republic of Bashkortostan.

Республика Башкортостан, 450008 Уфа, ул. Ленина 3; Республика Башкортостан, 450098 Уфа, проспект Октября, 71.

Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of BashkortostanРеспубликанский клинический онкологический диспансер Минздрава Республики БашкортостанBashkir State Medical University, Ministry of Health of RussiaБашкирский государственный медицинский университет Минздрава РоссииUfa Federal Research Center of the Russian Academy of SciencesУфимский федеральный исследовательский центр РАН250720211721391440611202018042021https://oncourology.abvpress.ru/oncur/article/view/1355

Prostate cancer is the leading cause of death among men. Existing prognostic factors make it possible to differentiate the degree of malignancy of tumors with high metastatic potential. Currently, the treatment of high-grade tumors is carried out with hormonal therapy, to which taxanes are added, when the malignant neoplasm becomes resistant to castration. Studies with other anti-cancer agents did not take into account the genetic background of the tumors, and most of the trials showed low response rates. The article describes an in silico approach for screening drug candidates that can be used as an alternative to taxanes. Researched 86 genes that distinguish between high and low grade tumors, and identified several genes that correlated with chemosensitivity. As an example, a set of six genes has been proposed the expression levels of which can predict cell sensitivity to oxaliplatin. The study demonstrates the relevance of an approach to the treatment of high-grade prostate cancer and new biomarkers for predicting clinical tumor response.

Рак предстательной железы - ведущая причина смертности у мужчин. Существующие прогностические факторы позволяют дифференцировать степень злокачественности опухолей с высоким метастатическим потенциалом. В настоящее время лечение опухолей высокой степени злокачественности проводится с помощью гормональной терапии, к которой добавляются таксаны в случае, когда злокачественное новообразование становится устойчивым к кастрации. Исследования с другими лекарственными препаратами не учитывали генетический фон опухолей, и результаты большинства испытаний продемонстрировали низкие показатели ответа. В статье описан подход in silico для скрининга кандидатов в препараты, которые могут быть использованы в качестве альтернативы таксанам. Исследовано 86 генов, различающих опухоли высокой и низкой степени злокачественности, и выполнена идентификация нескольких генов, которые коррелировали с химиочувствительностью. В качестве примера предложен набор из 6 генов, уровни экспрессии которых могут прогнозировать чувствительность клеток к оксалиплатину. Исследование демонстрирует актуальность подхода к лечению рака предстательной железы высокой степени злокачественности и новые биомаркеры для прогнозирования клинического ответа опухоли.

prostate canceroxaliplatinchemosensitivityGleason indexsilencingрак предстательной железыкорреляцияхимиочувствительностьсумма баллов по шкале ГлисонасайленсингBray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424. DOI: 10.3322/caac.21492.Siegel R.L., Miller K.D., Jemal A. et al. Cancer statistics 2018. CA Cancer J Clin 2018;68(1):7-30. DOI: 10.3322/caac.21442.Axel E.M., Matveev V.B. Statistics of malignant tumors of urinary and male urogenital organs in Russia and the countries of the former USSR. Onkourologiya = Cancer Urology 2019;15(2):15-24. (In Russ.). DOI: 10.17650/1726-9776-2019-15-2-15-24.Аксель Е.М., Матвеев В.Б. Статистика злокачественных новообразований мочевых и мужских половых органов в России и странах бывшего СССР. Онкоурология 2019;15(2):15-24. DOI: 10.17650/1726-9776-2019-15-2-15-24.Zhao Z., Stephan C., Weickmann S. et al. Tissue-based microRNAs as predictors of biochemical recurrence after radical prostatectomy: what can we learn from past studies? Int J Mol Sci 2017;18(10):2023. DOI: 10.3390/ijms18102023.Epstein J. Prostate cancer grading: a decade after the 2005 modified system. Mod Pathol 2018;31(S1):S47-63. DOI: 10.1038/modpathol.2017.133.Bulten W., Pinckaers H., van Boven H. et al. Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study. Lancet Oncol 2020;21(2):233-41. DOI: 10.1016/S1470-2045(19)30739-9.Grasso S., Wu Y.M., Robinson D.R. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487(7406):339-43. DOI: 10.1038/nature11125.Paller C.J., Antonarakis E.S. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther 2011;5:117-24. DOI: 10.2147/DDDT.S13029.Aloysius H., Hu L. Targeted prodrug approaches for hormone refractory prostate cancer. Med Res Rev 2015;35(3):554-85. DOI: 10.1002/med.21333.De Bono J.S., Logothetis C.L., Molina A. et al. Abiraterone and increased surviva in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005. DOI: 10.1056/NEJMoa1014618.Penney K.L., Sinnott J.A., Fall K. et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. Clin Oncol 2011;29(17):2391-6. DOI: 10.1200/JCO.2010.32.6421.Zhang L., Wan S., Jiang Y. et al. Molecular elucidation of disease biomarkers at the interface of chemistry and biology. J Am Chem Soc 2017;139(7):2532-40. DOI: 10.1021/jacs.6b10646.Rosenberg E.E., Gerashchenko G.V., Hryshchenko N.V. et al. Expression of cancer-associated genes in prostate tumors. Exp Oncol 2017;39(2):131-7. PMID: 29483498.Klahan S., Huang C.C., Chien S.C. et al. Bioinformatic analyses revealed underlying biological functions correlated with oxaliplatin responsiveness. Tumour Biol 2016;37(1):583-90. DOI: 10.1007/s13277-015-3807-2.Hu Z., Zhang D., Hao J. et al. Induction of DNA damage and p21-dependent senescence by Riccardin D is a novel mechanism contributing to its growth suppression in prostate cancer cells in vitro and in vivo. Cancer Chemother Pharmacol 2014;73(2):397-407. DOI: 10.1007/s00280-013-2365-9.Kaina B., Margison G.P., Christmann M. et al. Targeting O6 - methylguanine DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell Mol Life 2010;67(21):3663-81. DOI: 10.1007/s00018-010-0491-7.Fan L., Fei X., Zhu Y. et al. Comparative analysis of genomic alterations across castration-sensitive and castrationresistant prostate cancer via circulating tumor DNA sequencing. J Urol 2021;205(2):461-9. DOI: 10.1097/JU.0000000000001363.Abida W., Armenia J., Gopalan A. et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol 2017;2017:PO.17.00029. DOI: 10.1200/PO.17.00029.Lin H.P., Lin C.Y., Hsiao P.H. et al. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells. PLoS One 2013;8(12):e82625. DOI: 10.1371/journal.pone.0082625.Berg K.D., Vainer B., Thomsen F.B. et al. Protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. Eur Urol 2014;66(5):851-60. DOI: 10.1016/j.eururo.2014.02.058.Flavin R., Pettersson A., Hendrickson W.K. et al. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res 2014;20(18):4904-11. DOI: 10.1158/1078-0432.CCR-13-1341.Lei G., Liu S., Yang X., He C. TRIM29 reverses oxaliplatin resistance of P53 mutant colon cancer cell. Can J Gastroenterol Hepatol 2021;2021:8870907. DOI: 10.1155/2021/8870907.Chen Z., Gerke T., Bird V. et al. Trends in gene expression profiling for prostate cancer risk assessment: a systematic review. Biomed Hub 2017;2(2):1-15. DOI: 10.1159/000472146.Liu S., Garcia-Marques F., Zhang C.A. et al. Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay. Sci Rep 2021;11(1):7612. DOI: 10.1038/s41598-021-87155-5.Zhang B., Zhang Z., Hu H. et al. Novel gene signatures predictive of patient recurrence-free survival and castration resistance in prostate cancer. Cancers (Basel) 2021;13(4):917. DOI: 10.3390/cancers13040917.Downes M.R., Xu B., van der Kwast T.H. et al. Gleason grade patterns in nodal metastasis and corresponding prostatectomy specimens: impact on patient outcome. Histopathology 2019;75(5):715-22. DOI: 10.1111/his.13938.True L., Coleman I., Hawley S. et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 2006;103(29):10991-6. DOI: 10.1073/pnas.0603678103.Heger Z., Gumulec J., Cernei N. et al. Relation of exposure to amino acids involved in sarcosine metabolic pathway on behavior of non-tumor and malignant prostatic cell lines. Prostate 2016;76(7):679-90. DOI: 10.1002/pros.23159.Cortelo P.C., Demarque D.P., Dusi R.G. et al. A molecular networking strategy: high-throughput screening and chemical analysis of Brazilian cerrado plant extracts against cancer cells. Cells 2021;10(3):691. DOI: 10.3390/cells10030691.Puyo S., Houede N., Kaufmann A. et al. Gene expression signature predicting highgrade prostate cancer responses to oxaliplatin. Mol Pharmacol 2012;82(6):1205-16. DOI: 10.1124/mol.112.080333.Dhanasekaran S.M., Barrette T.R., Ghosh D. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6. DOI: 10.1038/35090585.Luo J., Duggan D.J., Chen Y. et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001;61(12):4683-8.Welsh J.B., Sapinoso L.M., Su A.I. et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61(16):5974-8.Best C.J., Gillespie J.W., Yi Y. et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005;11(19 Pt 1):6823-34. DOI: 10.1158/1078-0432.CCR-05-0585.Amaro A., Esposito A., Gallina A. et al. Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel. Cancer Metastasis Rev 2014;33(2-3):657-71. DOI: 10.1007/s10555-013-9470-4.Lapointe J., Li C., Giacomini C.P., Giacomini C. et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007;67(18):8504-10. DOI: 10.1158/0008-5472.CAN-07-0673.Singh D., Febbo P.G., Ross K. et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-9. DOI: 10.1016/s1535-6108(02)00030-2.Cunha G.R., Matrisian L.M. It's not my fault, blame it on my microenvironment. Differentiation 2002;70(9-10):469-72. DOI: 10.1046/j.1432-0436.2002.700901.x.Alonso J.C.C., Reis L.O., Garcia P.V. et al. steroid hormone receptors as potential mediators of the clinical effects of dutasteride: a prospective, randomized, double-blind study. Am J Mens Health 2017;11(1):126-33. DOI: 10.1177/1557988315602961.Gasent Blesa J.M., Marco V.G., Giner-Bosch V. et al. Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients. Am J Clin Oncol 2011;34(2):155-9. DOI: 10.1097/COC.0b013e3181d6b453.